Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OFD + PRF is a combination therapy consisting of Open Flap Debridement (OFD), a surgical periodontal procedure, and autologous Platelet-Rich Fibrin (PRF). OFD involves the reflection of a mucoperiosteal flap to allow access for thorough root debridement and cleaning of the periodontal pocket. PRF is a second-generation platelet concentrate prepared from the patient's own blood without the use of anticoagulants. It forms a fibrin matrix that acts as a scaffold and a reservoir for concentrated growth factors, including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor beta (TGF-β), and Vascular Endothelial Growth Factor (VEGF). These factors are released over a period of 7 to 14 days, promoting angiogenesis, cell proliferation, and osteogenesis. This combination is primarily used in the treatment of intrabony defects in patients with chronic periodontitis to enhance clinical attachment levels and reduce probing depths.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OFD + PRF.